ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Evolving Standards of Care

SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC

Haleigh Behrman
on: July 08, 2025In: Evolving Standards of Care, Meeting News, Society News
SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC

Dr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment. Read more


IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC

Haleigh Behrman
on: July 08, 2025In: Evolving Standards of Care, Meeting News, Society News
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC

The updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations. Read more

Bispecific T-cell Engagers: Understanding the Evolving and Innovative Approaches to Outpatient Side Effect Management

Joy Curzio
on: July 08, 2025In: Evolving Standards of Care, Supportive & Palliative Care
Bispecific T-cell Engagers: Understanding the Evolving and Innovative Approaches to Outpatient Side Effect Management

Dr. Melissa L. Johnson discusses evolving best practices for the operationalization of bispecific T-cell engagers, specifically tarlatamab. Read more

Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS

Joy Curzio
on: June 24, 2025In: Evolving Standards of Care, Meeting News, Society News
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS

Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher. Read more

A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC

Haleigh Behrman
on: June 24, 2025In: Evolving Standards of Care, Meeting News, Society News
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC

Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer. Read more

Rethinking Radiation: Adopting Hypofractionated Radiation Therapy

Haleigh Behrman
on: June 10, 2025In: Evolving Standards of Care, Radiation Oncology
Rethinking Radiation: Adopting Hypofractionated Radiation Therapy

Drs. Puneeth Iyengar and Edward Christopher Dee discuss the potential clinical and environmental benefits of hypofractionated radiation therapy, along with the barriers to broader adoption. Read more

Overcoming Resistance Remains a Challenge in Targeting KRAS

Haleigh Behrman
on: May 27, 2025In: Evolving Standards of Care, Meeting News, Names & News, Society News
Overcoming Resistance Remains a Challenge in Targeting KRAS

Dana-Farber's Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space. Read more

Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does?

Haleigh Behrman
on: May 27, 2025In: Evolving Standards of Care, Society News
Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does?

Drs. Mark Awad and Federica Pecci said recent findings suggest some patients with non-small cell lung cancer may experience survival benefits and disease control even after stopping ICI treatment. Read more

The Elephant in the Room: Addressing Oncology’s Carbon Footprint

Haleigh Behrman
on: May 13, 2025In: Evolving Standards of Care, Radiation Oncology
The Elephant in the Room: Addressing Oncology’s Carbon Footprint

From travel-related emissions to medical waste, Drs. Puneeth Iyengar and Edward Christopher Dee discuss the environmental impact of radiotherapy. Read more

Up in the Air: A Patient’s Perspective on Navigating Lung Cancer Treatment During One of the Most Devastating Wildfires in US History

Haleigh Behrman
on: April 22, 2025In: Evolving Standards of Care, Global Initiatives, Patient Advocacy
Up in the Air: A Patient’s Perspective on Navigating Lung Cancer Treatment During One of the Most Devastating Wildfires in US History

Lynn Lieberman was already in a fight against lung cancer, but she faced a second battle when the Los Angeles wildfires spread throughout her community. Read more

1234›»

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy